Sampada A. Patwardhan , Parikshit S. Prayag , Rajeev N. Soman , Bharat D. Purandare , S. Ramya , Romika Dawra , Rasika Joshi , Amrita P. Prayag
{"title":"Candida auris – Comparison of sensititre YeastOne and Vitek 2 AST systems for antifungal susceptibility testing – A single centre experience","authors":"Sampada A. Patwardhan , Parikshit S. Prayag , Rajeev N. Soman , Bharat D. Purandare , S. Ramya , Romika Dawra , Rasika Joshi , Amrita P. Prayag","doi":"10.1016/j.ijmmb.2024.100618","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p><em>Candida auris</em> is emerging as an important cause of candidemia and deep seated candidal infection. We compared the susceptibility results of bloodstream <em>Candida auris</em> isolates by Vitek 2 with Sensititre YeastOne (SYO) method.</p></div><div><h3>Methods</h3><p>Forty-seven <em>C. auris</em> blood stream isolates were simultaneously tested for AFST by Vitek 2 and SYO.</p></div><div><h3>Results</h3><p>All strains were resistant to Fluconazole. 25.5% isolates showed pan-azole resistance. In comparison with SYO, lower MICs for voriconazole were noted with Vitek 2 (VME rate 76.1%). All strains were sensitive to anidulafungin and micafungin by SYO. For micafungin, Vitek 2 demonstrated higher MICs and an ME rate of 23.5%. Susceptibility interpretation of caspofungin by SYO was challenged by development of ‘Eagle effect’ resulting in sensitivity of 28.2%. We studied the evolution of caspofungin ‘Eagle effect’ with SYO by serial hourly MIC readings and noted that paradoxical growth commenced at 21 hrs of incubation. Compared to SYO, Vitek 2 showed higher resistance rate to Amphotericin B with ME rate of 25.6%.</p></div><div><h3>Conclusion</h3><p>Laboratories using commercial AFST systems for <em>Candida auris</em> need to be aware of the possibility of ME and VME for amphotericin B and voriconazole respectively with Vitek 2 and ‘Eagle effect’ for caspofungin with SYO.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"50 ","pages":"Article 100618"},"PeriodicalIF":1.4000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085724000938","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Candida auris is emerging as an important cause of candidemia and deep seated candidal infection. We compared the susceptibility results of bloodstream Candida auris isolates by Vitek 2 with Sensititre YeastOne (SYO) method.
Methods
Forty-seven C. auris blood stream isolates were simultaneously tested for AFST by Vitek 2 and SYO.
Results
All strains were resistant to Fluconazole. 25.5% isolates showed pan-azole resistance. In comparison with SYO, lower MICs for voriconazole were noted with Vitek 2 (VME rate 76.1%). All strains were sensitive to anidulafungin and micafungin by SYO. For micafungin, Vitek 2 demonstrated higher MICs and an ME rate of 23.5%. Susceptibility interpretation of caspofungin by SYO was challenged by development of ‘Eagle effect’ resulting in sensitivity of 28.2%. We studied the evolution of caspofungin ‘Eagle effect’ with SYO by serial hourly MIC readings and noted that paradoxical growth commenced at 21 hrs of incubation. Compared to SYO, Vitek 2 showed higher resistance rate to Amphotericin B with ME rate of 25.6%.
Conclusion
Laboratories using commercial AFST systems for Candida auris need to be aware of the possibility of ME and VME for amphotericin B and voriconazole respectively with Vitek 2 and ‘Eagle effect’ for caspofungin with SYO.
期刊介绍:
Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study.
Review articles, Special Articles or Guest Editorials are accepted on invitation.